Advised Lixis SA on its sale to global pharma inspection company SEA Vision
Advised on the cross-border sale of pharmaceutical quality control company Lixis, to SEA Vision, a global leader in pharmaceutical inspection systems. Terms of the transaction were not disclosed.
SEA Vision is an Italian company specializing in vision and track-andtrace systems for the pharmaceutical industry, with a consolidated turnover of €60 million.
Lixis is an Argentinian company with over 17 years of experience in pharmaceutical vision, control and track-andtrace systems. The operational synergies between the companies will enable SEA Vision to become the leading group providing both software and hardware in its target market in Latin America, with a local workforce of 70 professionals.
Lixis has already been collaborating with SEA Vision in the Brazilian market through the São Paulo-based subsidiary SEA Vision Latin America (SVLA).
IMAP Argentina, led by Pablo Teubal and Pedro Querio, acted as exclusive financial advisor to Lixis.
Bedankt voor je interesse in IMAP. Gebruik onderstaande formulier om ons meer te vertellen over je huidige situatie, dan zorgen wij ervoor dat de juiste M&A expert zo snel mogelijk contact met je opneemt.